B-Temia defines its mission as “helping people regain their autonomy through mobility, with dignity and confidence, and thus improve their quality of life”.
With its dedicated team of engineers, technicians, manufacturing and customer service specialists, focusing on the development, the production and the commercialization of bio-robotic powered assistive devices for human mobility, the company aims at becoming the global leader in the high growth market of human augmentation.
Its proprietary technology called “DermoskeletonTM” provides the user with additional strength and mechanical assistance to the movement for the recovery, support, and increase of biomechanical functions.
In 2015, five years after its foundation, B-Temia launches “KEEOGO”, its first medical product, that assists people who are gradually losing their autonomy in walking due to a neuro or ortho-degenerative disease such as Parkinson’s, stroke, Multiple Sclerosis, or knee/hip osteoarthritis. KEEOGO is duly approved by Health Canada; it received its CE-Marking in December 2019; the FDA clearance for the U.S. market and the authorization to be commercialized in Taiwan in September 2020. It is currently available in Canada, in Europe, in Asia and in the United States, and is manufactured in three locations: Chongqing (China), Taiwan and Quebec City (Canada).
Beside the medical market, B-Temia applies its DermoskeletonTM technology to military purposes as a preventive tool against musculoskeletal injuries and physical exhaustion of soldiers. B-Temia has partnered with Lockheed Martin Company since 2016, with the objective of creating and distributing the ONYX, the industrial version of its DermoskeletonTM technology. The name of the company, B-temia comes from the word blastema, that designates a mass of cells capable of growth and regeneration into organs or body parts, and refers to B-Temia’s capability to regenerate biomechanical functions of the human body.